Lung-RADS 4类结节管理算法的成本效果评价
该回顾性研究基于151例Lung-RADS 4类结节患者模拟10万例队列,比较不同指南管理算法的健康结局与成本。BTS算法获得最多QALYs(10.041),其次为ACCP(10.035)和Lung-RADS(10.021);仅BTS和Lung-RADS位于有效前沿,ICER为52 634美元(95%CI:45 122,60 619)。结论认为BTS和Lung-RADS对4类结节管理均具成本效果,BTS的QALYs更高。
要点
- Lung-RADS 4类结节管理中,BTS算法QALYs最高,Lung-RADS次之。
- 仅BTS和Lung-RADS位于成本效果有效前沿,ICER为52 634美元。
- 多数敏感性分析下BTS与Lung-RADS仍为有效前沿算法。
核心结论
- BTS算法与Lung-RADS对Lung-RADS 4类结节的管理均具成本效果,BTS产生更多QALYs。
研究设计与样本
- 回顾性研究,基于2010年1月至2018年8月151例Lung-RADS 4类结节患者模拟100 000例患者队列。
- 每位模拟患者分别按各管理算法处理,根据干预措施和癌症诊断延迟累积健康结局,计算QALYs并累积干预与癌症治疗成本。
- 若算法漏诊癌症,则在下一年度筛查轮次诊断,期间结节会生长;根据结节是否恶性分配年龄别或癌症别死亡率。
- 进行单因素敏感性分析。
诊断标准与关键数值
- BTS算法QALYs为10.041,ACCP为10.035,Lung-RADS为10.021。
- 仅BTS和Lung-RADS位于有效前沿,ICER为52 634美元(95%CI:45 122,60 619)。
- BTS对比Lung-RADS的ICER在所有情景下均低于100 000美元, except无癌症患者预期寿命增加时ICER为109 273美元。
临床应用与阅片要点
- 对于Lung-RADS 4类结节,可优先考虑BTS或Lung-RADS算法进行管理,两者均具成本效果。
- BTS算法在健康获益(QALYs)上略优于Lung-RADS,但需结合本地资源与患者偏好选择。
局限性
- 研究为基于151例患者的模拟队列,结果外推需谨慎。
- 回顾性设计可能引入选择偏倚。
- 成本数据可能因地区和时间差异而不具普适性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate nodule management guidelines in a simulated cohort of Lung Reporting and Data System (Lung-RADS) 4 nodules based on real-world data.
MATERIALS AND METHODS: In this retrospective study, 100 000 patients were simulated from 151 patients with Lung-RADS 4 nodules (from January 2010 to August 2018). Each patient in the simulation was managed with each algorithm, and health outcomes were accumulated based on interventions and delays to cancer diagnosis. If the algorithm missed a cancer, it was diagnosed at the next annual screening round, although it would grow in the interim. Patient age-specific or cancer-specific mortality was assigned depending on whether the nodule was malignant, and quality-adjusted life years (QALYs) were calculated. Costs of interventions and cancer treatment were accumulated. One-way sensitivity analyses were performed.
RESULTS: The most effective algorithm was the British Thoracic Society (BTS; 10.041 QALYs), followed by the American College of Chest Physicians (10.035 QALYs) and Lung-RADS (10.021 QALYs). Only the BTS and Lung-RADS were on the efficient frontier, with an incremental cost-effectiveness ratio (ICER) of $52 634 (95% CI: $45 122, $60 619). Under nearly all sensitivity analyses, the only algorithms on the efficient frontier were BTS and Lung-RADS. The ICERs for BTS versus Lung-RADS were under $100 000 for all scenarios except an increased life expectancy in patients without cancer, in which case the ICER was $109 273.
CONCLUSION: The BTS algorithm and Lung-RADS were cost-effective for managing category 4 nodules, with BTS yielding greater QALYs.Supplemental material is available for this article.© RSNA, 2021See also the commentary by Elicker in this issue.
引用
- Hammer MM, Gupta S, Kong CY, et al. Cost-Effectiveness of Management Algorithms for Lung-RADS Category 4 Nodules. Radiol Cardiothorac Imaging. 2021. PMID: 33969309. doi:10.1148/ryct.2021200523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。